-
Patient access to medicines for rare diseases in European countriesDetiček, Andreja, farmacevtka ; Locatelli, Igor ; Kos, Mitja, 1973-Background The number of authorized orphan and non-orphan medicines for rare diseases has increased in Europe. Patient access to these medicines is affected by high costs, weak efficacy/safety ... evidence, and societal value. European health care systems must determine whether paying for expensive treatments for only a few patients is sustainable. Objectives This study aimed to evaluate patient access to orphan and non-orphan medicines for rare diseases in 22 European countries during 2005 to 2014. Methods Medicines for rare diseases from the Orphanet list, authorized during 2005 to 2014, were searched for in the IMS MIDAS Quarterly Sales Data, January 2005 - December 2014 (IQVIA, Danbury, CT). The following three measures were determined for each country: number of available medicines, median time to continuous use, and medicine expenditure. A medicine was considered available if uninterrupted sales within a 1-year period were detected. Results From 2005 to 2014, 125 medicines were authorized and 112 were found in the search. Of those, between 70 (63%) and 102 (91%) were available in Germany, the United Kingdom, Italy, France, and the Scandinavian countries. These countries were also the fastest to enable continuous use (3%9 mo). Only 27% to 38% of authorized medicines were available in Greece, Ireland, Bulgaria, Romania, and Croatia, which took 1 to 2.6 years to begin continuous use. A country%s expenditure on medicines for rare diseases in 2014 ranged between %0.2 and %31.9/inhabitant. Conclusions Patient access to medicines for rare diseases varies largely across Europe. Patients in Germany, Scandinavian countries, Switzerland, France, and the United Kingdom can access larger numbers of medicines in shorter time.Source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. - ISSN 1098-3015 (Vol. 21, iss. 5, 2018, str. 553-560)Type of material - article, component partPublish date - 2018Language - englishCOBISS.SI-ID - 4490097
Author
Detiček, Andreja, farmacevtka |
Locatelli, Igor |
Kos, Mitja, 1973-
Topics
Bolezni |
Pacienti |
zdravstvo |
redke bolezni |
Evropa |
dostop do zdravil |
health services |
elderly people |
Europe |
analysis
![loading ... loading ...](themes/default/img/ajax-loading.gif)
source: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. - ISSN 1098-3015 (Vol. 21, iss. 5, 2018, str. 553-560)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|---|
Detiček, Andreja, farmacevtka | 37547 |
Locatelli, Igor | 24399 |
Kos, Mitja, 1973- | 20374 |
Select pickup location:
Material pickup by post
Notification
Subject headings in COBISS General List of Subject Headings
Select pickup location
Pickup location | Material status | Reservation |
---|
Please wait a moment.